AICAR

AICAR is not a peptide. It is a small molecule — an intermediate in the pathway cells use to build purines, the components of DNA and of the energy carrier ATP. Taken into a cell, it is phosphorylated into a compound called ZMP, and ZMP is close enough in shape to AMP that the cell's energy sensor cannot tell them apart.

That confusion is the entire point. Cells judge their energy state by the ratio of ATP, which is charged, to AMP, which is spent. When AMP rises the cell concludes it is running short and switches to conservation: burn fuel, stop building. ZMP triggers that conclusion without any actual shortfall, which makes it possible to study the response in isolation from the exhaustion that normally causes it.

This is why AICAR became known as an exercise mimetic — a label worth reading carefully. A 2008 study reported that sedentary mice given the compound ran substantially further than controls, which produced a great deal of attention. What it demonstrated is that one pathway activated by exercise can be activated chemically, not that a compound can substitute for exercise.

• Activating AMPK directly: AMPK is the master energy sensor in every cell, and this is the standard laboratory tool for switching it on. A large part of what is known about the pathway was established using it.

• Separating cause from consequence: Exercise changes hundreds of things at once. Activating one pathway chemically in a resting animal is how researchers determine which downstream effects belong to that pathway specifically.

• Mitochondrial biogenesis: Sustained AMPK activation prompts cells to build more mitochondria. Studying how a short-term energy signal produces a long-term structural change is a central question in muscle biology.

• Why it did not become a medicine: It is absorbed poorly, cleared rapidly and requires very large amounts to act. It is a well-documented case of a compound that works in the laboratory and cannot practically leave it.

ATP is the currency cells spend to do work. Spending it produces ADP and then AMP, so a rising proportion of AMP is a direct signal that reserves are being depleted. Cells monitor that ratio with an enzyme called AMP-activated protein kinase, AMPK, which acts as a thermostat for energy.

When AMPK switches on it does two things at once. It turns on processes that generate energy — fatty acid oxidation, glucose uptake, the building of new mitochondria — and turns off processes that consume it, such as making fat and synthesising protein. This is a coordinated shift from spending to earning, and it is one of the most conserved regulatory systems in biology.

AICAR intervenes by imitation. Inside the cell it becomes ZMP, which resembles AMP closely enough to bind the same site on AMPK and activate it. The cell mounts a full low-energy response while its actual energy state is unchanged. That is what makes it an excellent experimental tool, and also what makes the exercise-mimetic framing misleading: exercise activates this pathway among a great many others, and reproducing one of them is not reproducing exercise.

As a research tool the evidence is strong and long-standing. AICAR has been used to activate AMPK since the 1990s, its conversion to ZMP is established, and much of the foundational work on the AMPK pathway depends on it. The mouse endurance finding was published in a leading journal and has been widely discussed.

It remains a laboratory compound: absorption is poor, clearance rapid, and no approved indication exists. It is prohibited in competitive sport and is supplied for laboratory research only. As an instrument it is long established — much of what is known about the AMPK pathway was worked out with it, and it is still the standard way to switch that pathway on.

SLU-PP-332 pursues the same idea through a different mechanism, acting on nuclear receptors that control the genes for mitochondrial function rather than on the energy sensor itself. The two are the clearest illustration of how differently the transcriptional and signalling routes to the same outcome behave.

5-Amino-1MQ is a third approach again — enzyme inhibition rather than activation — while AOD-9604 shows what happens when a compound in this space actually reaches a clinical trial.